Application of Mycobacterial Proteomics to Vaccine Design: Improved Protection by Mycobacterium bovis BCG Prime-Rv3407 DNA Boost Vaccination against Tuberculosis
- 1 November 2004
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 72 (11) , 6471-9
Abstract
Information from comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis bacillus Calmette-Guérin (BCG) principally allows prediction of potential vaccine candidates. Thirty-six M. tuberculosis DNA vaccine candidates identified by comparative proteome analysis were evaluated in the mouse model for protection against low-dose aerosol M. tuberculosis infection. We identified the DNA vaccine candidate Rv3407 as a protective antigen and analyzed putative major histocompatibility complex class I epitopes by computational predictions and gamma interferon Elispot assays. Importantly, we discovered that the DNA vaccine Rv3407 improved the efficacy of BCG vaccination in a heterologous prime-boost vaccination protocol. Our data demonstrate the rationale of a combination of proteomics, epitope prediction, and broad screening of putative antigens for identification of novel DNA vaccine candidates. Furthermore, our experiments show that heterologous prime-boost vaccination with a defined antigen boost “on top” of a BCG primer provides superior protection against tuberculosis over vaccination with BCG alone.Keywords
This publication has 50 references indexed in Scilit:
- A DNA Prime- Mycobacterium bovis BCG Boost Vaccination Strategy for Cattle Induces Protection against Bovine TuberculosisInfection and Immunity, 2003
- Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteersVaccine, 2003
- Construction and immunogenicity in a prime–boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccineJournal of General Virology, 2003
- The World Health Report 2002 - Reducing Risks, Promoting Healthy LifeEducation for Health, 2003
- Slowly Declining Levels of Viral RNA and DNA in DNA/Recombinant Modified Vaccinia Virus Ankara-Vaccinated Macaques with Controlled Simian-Human Immunodeficiency Virus SHIV-89.6P ChallengesJournal of Virology, 2002
- Immunization of Rhesus Macaques with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen Induces Broad Simian Immunodeficiency Virus (SIV)-Specific T-Cell Responses and Reduces Initial Viral Replication but Does Not Prevent Disease Progression following Challenge with Pathogenic SIVmac239Journal of Virology, 2002
- Immunology of TuberculosisAnnual Review of Immunology, 2001
- DNA Vaccines: Immunology, Application, and OptimizationAnnual Review of Immunology, 2000
- Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequenceNature, 1998
- DNA VACCINESAnnual Review of Immunology, 1997